<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13D
(RULE 13D-101)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULE 13D-1(A) AND AMENDMENTS THERETO FILED PURSUANT TO
RULE 13D-2(A)
(AMENDMENT NO. 4)
ISIS PHARMACEUTICALS, INC.
------------------------------------------------------------------
(Name of Issuer)
COMMON STOCK, PAR VALUE $0.001 PER SHARE
------------------------------------------------------------------
(Title of Class of Securities)
464330 10 9
------------------------------------------------------------------
(Cusip Number)
HANS-PETER MUELLER
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
BINGER STRASSE 173
D-55216 INGELHEIM AM RHEIN, GERMANY
011-49-61-32-77-2414
AND
KLAUS H. JANDER, ESQ.
CLIFFORD CHANCE ROGERS & WELLS LLP
200 PARK AVENUE
NEW YORK, NY 10166
(212) 878-8000
------------------------------------------------------------------
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
JULY 5, 2000
------------------------------------------------------------------
(Date of Event Which Requires Filing of This Statement)
If the filing person has previously filed a statement on Schedule 13G to
report the acquisition that is the subject of this Schedule 13D, and is filing
this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the
following box |_|
Note. Schedules filed in paper format should include a signed original and five
copies of the schedule, including all exhibits. See Rule 13d-7(b) for the other
parties to whom copies are to be sent.
(Continued on following pages)
(Page 1 of 5 Pages)
<PAGE> 2
--------------------- -----------------
CUSIP NO. 464330 10 9 13D PAGE 2 OF 5 PAGES
--------------------- -----------------
--------------------------------------------------------------------------------
1. NAMES OF REPORTING PERSONS
S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Boehringer Ingelheim International GmbH
--------------------------------------------------------------------------------
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a)|_|
(b)|_|
--------------------------------------------------------------------------------
3. SEC USE ONLY
--------------------------------------------------------------------------------
4. SOURCES OF FUNDS
OO
--------------------------------------------------------------------------------
5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEM 2(d) OR 2(e)
|_|
--------------------------------------------------------------------------------
6. CITIZENSHIP OR PLACE OF ORGANIZATION
Federal Republic of Germany
--------------------------------------------------------------------------------
7. SOLE VOTING POWER
1,805,407
NUMBER OF ---------------------------------------------------------
UNITS 8. SHARED VOTING POWER
BENEFICIALLY
OWNED BY 0
EACH ---------------------------------------------------------
REPORTING 9. SOLE DISPOSITIVE POWER
PERSON WITH
1,805,407
---------------------------------------------------------
10. SHARED DISPOSITIVE POWER
0
--------------------------------------------------------------------------------
11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,805,407
--------------------------------------------------------------------------------
12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES
|_|
--------------------------------------------------------------------------------
13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
4.71%
--------------------------------------------------------------------------------
14. TYPE OF REPORTING PERSON
CO
--------------------------------------------------------------------------------
<PAGE> 3
SCHEDULE 13D
FILED PURSUANT TO RULE 13d-1
OF THE GENERAL RULES AND REGULATIONS UNDER
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED
This Amendment No. 4, which relates to shares of the common stock, par
value $0.001 per share (the "Common Stock") of Isis Pharmaceuticals, Inc. (the
"Issuer") and is being filed by Boehringer Ingelheim International GmbH
("Boehringer"), supplements and amends the statement on Schedule 13D, originally
filed with the Commission on July 28, 1995, as amended by Amendment No. 1, filed
with the Commission on December 23, 1996, Amendment No. 2, filed with the
Commission on September 2, 1999, and Amendment No. 3 filed with the Commission
on June 12, 2000.
ITEM 5. INTEREST IN THE SECURITIES OF THE ISSUER.
Item 5 is hereby amended to read in its entirety as follows:
(a) Beneficial Ownership: 1,805,407
Percentage Ownership: 4.71%
(b) Sole Voting Power: 1,805,407
Shared Voting Power: -0-
Sole Dispositive Power: 1,805,407
Shared Dispositive Power: -0-
(c) Recent Transactions: The following table sets forth sales of
shares of Common Stock by Boehringer
since June 5, 2000. Such sales were
effected on the open market over the
Nasdaq Stock Market by a broker.
APPROXIMATE PRICE
AMOUNT OF PER SHARE
DATE SHARES (exclusive of commissions)
---- --------- --------------------------
6/6/00 40,000 $11.2500
6/8/00 5,800 $13.0000
6/13/00 200 $13.2500
6/14/00 1,500 $13.1250
6/19/00 20,000 $13.0000
6/20/00 20,000 $13.5000
6/21/00 20,000 $14.0622
6/22/00 9,000 $14.0000
6/26/00 20,000 $13.0187
6/28/00 20,000 $13.0078
6/29/00 20,000 $13.0000
6/30/00 20,000 $14.2500
7/3/00 8,200 $14.5625
7/5/00 20,000 $14.2538
3
<PAGE> 4
(d) Right to Receive Dividends: Not Applicable
(e) Ownership below 5%: Boehringer ceased to be the
beneficial owner of more than 5%
of the outstanding Common Stock
on June 22, 2000.
4
<PAGE> 5
SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Dated: July 11, 2000
BOEHRINGER INGELHEIM INTERNATIONAL GmbH
By: /s/ Mueller
Name: Mr. Mueller
Title: Authorized Signatory
By: /s/ Schoeberl
Name: Dr. Schoeberl
Title: Authorized Signatory
5
